Pfizer, the world’s third largest pharmaceutical company based on prescription drug sales, is receiving a massive injection of revenue from its COVID-19 vaccine. Pfizer projects that revenue will almost double in 2021 compared to 2020. BNT162b2, as Pfizer’s vaccine is officially called, is expected to account for more than 40% of Pfizer’s revenue for the year, dwarfing any other drug in its vast portfolio. (Chart from statista.com
Jeffrey Cerny